XIDX
BMHS
Market cap74mUSD
Nov 12, Last price
155.00IDR
Name
Bundamedik Tbk PT
Chart & performance
P/E
107.38
P/S
0.83
EPS
1.44
Div yield, %
0.36%
Shrs. gr., 5y
-2.67%
Rev. gr., 5y
7.05%
Revenues
1.61t
+3.84%
Net income
12.42b
+3.98%
CFO
250.62b
+637.57%
Dividend
Jun 23, 20261.03 IDR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating as a key healthcare provider in Indonesia, PT Bundamedik Tbk (also known as PT Bunda Medik) had a significant footprint as of December 31, 2021. Its facilities included two maternal and child hospitals, three general hospitals, two clinics, ten specialized in-vitro fertilization (IVF) centers, and fourteen diagnostic laboratories. Beyond its direct medical services, the company diversified into the distribution of pharmaceuticals and medical equipment, alongside interests in the hotel industry, medical tourism, and management consulting. Established in 1973, PT Bundamedik Tbk is headquartered in Jakarta Pusat, Indonesia, and operates as a subsidiary of PT Bunda Investama Indonesia.
Key people
Ivan Sini
President Commissioner · since 2019
Mesha Sini
President Director · since 2019
Wishnutama Kusubandio
Independent Deputy President Commissioner · since 2021
Tedy Homogin
Director · since 2021
Taufik Santoso
Director · since 2019
Nurhadi Yudiyantho
Director · since 2019
Josephine Tobing
Corporate Secretary · since 2014
Sunata Osampurno
Commissioner · since 2025
Rito Alam Sini
Commissioner · since 2019
Chairul Nasution
Independent Commissioner · since 2021
Valuation
Title IDR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||